Eltrombopag for the treatment of refractory connective tissue disease-related thrombocytopenia: a pilot study of 52 cases
For refractory CTD-ITP patients, Eltrombopag demonstrated significant clinical improvement, safety, and a steroid-sparing effect with prolonged use. Patient characteristics at baseline may affect treatment efficacy.
Authors
- Shaozhe Cai (ORCID: https://orcid.org/0000-0001-6778-9745)
- Ziwei Hu (ORCID: https://orcid.org/0000-0003-3552-2143)
- Siying Deng
- Lingli Dong (ORCID: https://orcid.org/0000-0003-1296-5021)
- Bei Wang (ORCID: https://orcid.org/0000-0001-8326-1385)
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Arthritis Research & Therapy
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1186/s13075-024-03472-w
- Citations
- 3
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.31
Funders
- National Natural Science Foundation of China
- Tongji University